JESUS MIGUEL
UNDA URZAIZ
Investigador/a en el periodo 2002-2023
Hospital Universitario Puerta del Mar
Cádiz, EspañaPublicaciones en colaboración con investigadoras/es de Hospital Universitario Puerta del Mar (10)
2024
-
Why is it necessary to produce a BCG strain in Spain?
Actas Urologicas Espanolas
2023
-
A multidisciplinary consensus statement on the optimal pharmacological treatment for metastatic hormone-sensitive prostate cancer
Actas Urologicas Espanolas, Vol. 47, Núm. 2, pp. 111-126
-
Abiraterone in low-volume metastatic hormone-sensitive prostate cancer. Authors’ reply
Actas Urologicas Espanolas
-
Hormone sensitive protocol for metastatic prostate cancer, an update
Actas Urologicas Espanolas, Vol. 47, Núm. 4, pp. 244-249
-
Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial
European urology oncology, Vol. 6, Núm. 1, pp. 58-66
2022
-
Non-metastatic castration-resistant prostate cancer: management recommendations
Actas Urologicas Espanolas, Vol. 46, Núm. 4, pp. 193-213
2019
-
Safety of nivolumab in metastatic renal cell carcinoma patients: A real-life experience in a Spanish urology setting
Actas Urologicas Espanolas, Vol. 43, Núm. 7, pp. 364-370
2014
2013
-
Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study
British Journal of Cancer, Vol. 109, Núm. 1, pp. 121-130
-
Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study
British Journal of Cancer, Vol. 108, Núm. 12, pp. 2565-2572